(Q51608331)

8 April 2018

title

A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia (English)

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

20 November 2022

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

20 November 2022

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

20 November 2022

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

20 November 2022

author name string

S. J. Gallacher

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773137

20 November 2022

S. H. Ralston

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773137

20 November 2022

W. D. Fraser

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773137

20 November 2022

F. J. Dryburgh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773137

20 November 2022

R. A. Cowan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773137

20 November 2022

F. C. Logue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773137

20 November 2022

I. T. Boyle

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773137

20 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1773137

20 November 2022

publication date

1 December 1991

1 reference

8 April 2018

full work available at URL

https://api.elsevier.com/content/article/PII:016960099190130R?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

https://api.elsevier.com/content/article/PII:016960099190130R?httpAccept=text/plain

20 November 2022

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

20 November 2022

1 reference

8 April 2018

volume

15

1 reference

8 April 2018

issue

3

1 reference

8 April 2018

page(s)

249-256

1 reference

8 April 2018

Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

20 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia

20 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia

20 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia

20 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP

20 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy

20 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Hypercalcaemia and metastatic bone disease: is there a causal link?

20 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Predictive value of derived calcium figures based on the measurement of ionised calcium.

20 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

A Two-Site Immunoradiometric Assay for Pth(1–84) Using N and C Terminal Specific Monoclonal Antibodies

20 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Arginine infusion blocks the action of parathyroid hormone but not arginine vasopressin on the renal tubule in man

20 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Nomogram for derivation of renal threshold phosphate concentration

20 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

20 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.

20 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

20 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

APD in Paget's disease of bone. Role of the mononuclear phagocyte system?

20 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Chronic high-dose pamidronate in refractory malignant hypercalcaemia

20 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

Dose of bisphosphonate for hypercalcaemia of malignancy

20 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/0169-6009(91)90130-R

20 November 2022

Identifiers

1 reference

8 April 2018

1 reference

8 April 2018